Abstract Body

The latent HIV-1 reservoir remains one of the major obstacles to cure HIV. To monitor HIV cure strategies, a validated biomarker is needed that can evaluate the reservoir over time in vivo. Consequently, numerous assays are now being investigated to estimate the size of the replication competent provirus. 

A comprehensive study was designed to evaluate and compare potential HIV-1 reservoir biomarkers. A cohort of 25 ART treated patients was sampled in which plasma viral load (<50 cp/ml) was suppressed for median of 7 years (5-11). Total, integrated HIV-1 DNA and unspliced (us-) HIV-1 RNA were quantified in peripheral blood. A quantitative viral outgrowth assay (qVOA) was performed. Subsequently, a nested substudy of 10 patients was set-up to analyse HIV-1 integration sites and tat/rev induced limiting dilutions assay (TILDA). The selected patients had low level of total HIV-1 DNA (<250 cp/106PBMCs) or high level of qVOA (> 2 IUPM). The percentage of integration site clonality was estimated based on results from the integration site analysis, and the frequency of cells with inducible HIV RNA transcription were estimated using maximum likelihood method. 

Integrated and total HIV-1 DNA were detected in all patients, and both measures correlated well (p=0.002, R²=0.85). Replication-competent virus was detected in 80% of patients by the qVOA and this correlated with integrated and total HIV-1 DNA (p=0.05, R²=0.44; p = 0.019, R²=0.54; respectively). In total 317 integration sites were analysed. A wide range of percentage of clonality (25.0-91.4%) was observed between patients. The majority of patients had an average of 30% clonality, which on average comprised of 3.4 predominant clonal integration sites per patient. Patients with higher clonal diversity (≥ 6 clones) had higher estimate for TILDA (frequency of cells with inducible msRNA  > 200 cells /106 PBMCs) and higher CD4 nadir count (p=0.048, R²=0.46). Interestingly, one patient had an extremely high clonality (>90%), which was represented by a single clone. This patient also had no inducible virus in both VOA and TILDA, suggesting that the clonal provirus in this patient is replication incompetent. The single predominant clone was associated with the extremely CD4 nadir count in this patient (3 cells/ul.)

We observed a good correlation between VOA and integrated and total HIV-1 DNA. Integration site sequencing revealed that most of the ART treated patients in this study had an HIV DNA reservoir consisting of 30% clonally expanded cells. These levels of clonal provirus did not affect the amount of inducible virus, except for the one patient with >90% clonality.